Oklo Supports Executive Order to Bolster Nuclear Energy
Oklo Inc. (NYSE: OKLO) shares gained ground Wednesday. The company, an advanced nuclear technology concern, issued a statement of support in response to the White House’s release of a series of executive orders focused on speeding up approval and adoption of advanced nuclear, reforming the Nuclear Regulatory Commission (NRC), restoring the domestic nuclear supply chain, and overhauling testing and licensing processes for advanced nuclear.This morning’s news release went on to say that, as part of the announcement, Oklo co-founder and CEO Jacob DeWitte joined President Trump at the White House alongside other industry leaders. The event marked a historic moment in the administration’s effort to secure America’s energy future and unleash American energy dominance.“These executive orders are about enabling deployment. They show clear alignment around the need to modernize how we license, fuel, and build advanced nuclear power to meet rising demand,” said Jacob DeWitte, co-founder and CEO of Oklo.The executive orders direct agencies such as the Department of Energy (DOE) and the Department of Defense (DoD) to operate more effectively as both customers and enablers of new energy technologies. Oklo supports efforts to empower the DOE, DoD, and NRC to use existing authorities more efficiently and to prioritize performance-based, mission-aligned reviews.Oklo says it is developing U.S. invented fast fission power plants capable of recycling used nuclear material and converting it into clean, firm power. OKLO shares took on 93 cents, or 1.7%, to $55.13.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


